Ponatinib
| Clinical data | |
|---|---|
| Pronunciation | /poʊˈnætɪnɪb/ poh-NAT-i-nib |
| Trade names | Iclusig |
| Other names | AP24534 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a613029 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Unknown |
| Protein binding | >99% (in vitro) |
| Metabolism | Liver (CYP3A4, 2C8, 2D6, 3A5) |
| Elimination half-life | 12–66 hours |
| Excretion | Feces (87%), urine (5%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C29H27F3N6O |
| Molar mass | 532.571 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ponatinib, sold under the brand name Iclusig, is a medication used for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia. It was developed by Ariad Pharmaceuticals. It is a multi-targeted tyrosine-kinase inhibitor. Some forms of chronic myeloid leukemia, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors.
Ponatinib was approved for medical use in the United States in December 2012, and in the European Union in July 2013.